Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors

AIDS

Volumn 20, Issue 16, 2006, Pages 2065-2073

  Yoshimura, Kazuhisa ^a   Shibata, Junji ^a   Kimura, Tetsuya ^a   Honda, Akiko ^a   Maeda, Yosuke ^a   Koito, Atsushi ^a   Murakami, Toshio ^b   Mitsuya, Hiroaki ^a   Matsushita, Shuzo ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Anti V3 monoclonal antibody; Broadly neutralizing; CCR5 inhibitor; HIV 1; KD 247; Synergism

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; AMPRENAVIR; APLAVIROC; CD4 ANTIBODY; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTIBODY; DIDANOSINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; KD 247; LAMIVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NELFINAVIR; NEUTRALIZING ANTIBODY; RANTES; RECOMBINANT ANTIGEN; RECOMBINANT CD4 ANTIGEN; SAQUINAVIR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SYNERGISM; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; TRANSFECTION;

EID: 33750263710     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000247587.31320.fe     Document Type: Article

References (20)

1. Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K, Yonemura H, et al. Sequential immunization with V3 peptides from primary HIV-1 produces cross-neutralizing antibodies against primary isolates with matching narrow neutralization sequence motif. J Virol 2006; 80:5552-5562.
2. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990; 249:932-935.
3. Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol 2006; 80:5563-5570.
4. Yusa K, Maeda Y, Fujioka A, Monde K, Harada S. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 2005; 280:30083-30090.
5. Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998; 72:6988-6996.
6. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96:5698-5703.
7. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98:12718-12723.
8. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78:8654-8662.
9. Maeda Y, Foda M, Matsushita S, Harada S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol 2000; 74: 1787-1793.
10. Yoshimura K, Feldman R, Kodama E, Kavlick F, Qiu YL, Zemlicka J, et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother 1999; 43:2479-2483.
11. Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, et al. A potent human immunodeficiency virus type 1 protease inhibitor,UIC-94003 (TMC-126), and selectionof a novel (A28S) mutation in the protease active site. J Virol 2002; 76:1349-1358.
12. Hope TJ, Huang XJ, McDonald D, Parslow TG. Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. Proc Natl Acad Sci USA 1990; 87:7787-7791.
13. Wang FX, Kimura T, Nishihara K, Yoshimura K, Koito A, Matsushita S. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J Infect Dis 2002; 185:608-617.
14. Chou TC, Hayball MP. CalcuSyn. 2nd edn. Cambridge, UK: Biosoft; 1996.
15. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977; 252:6438-6442.
16. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201:1407-1419.
17. Kuiken C, Foly B, Hahn BH, Marx P, McCutchan F, Mellors J, et al. HIV Sequence Compendium. Los Alamos: Los Alamos National Laboratory; 2001.
18. Richman DD. HIV chemotherapy. Nature 2001; 410:995-1001.
19. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Ballota C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
20. Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005; 338: 182-199.